12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Xarelto rivaroxaban from Bayer to treat deep vein thrombosis (DVT) and prevent recurrent DVT and pulmonary embolism following an acute DVT - its approved indication. NICE said the provided data failed to demonstrate...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >